Compare CMTL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | IVVD |
|---|---|---|
| Founded | 1967 | 2020 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 437.1M |
| IPO Year | 2024 | 2021 |
| Metric | CMTL | IVVD |
|---|---|---|
| Price | $5.10 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $8.75 |
| AVG Volume (30 Days) | 218.3K | ★ 1.7M |
| Earning Date | 03-16-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | $53,426,000.00 |
| Revenue This Year | N/A | $143.48 |
| Revenue Next Year | $1.97 | $25.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $1.19 | $0.46 |
| 52 Week High | $6.21 | $3.07 |
| Indicator | CMTL | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 57.57 |
| Support Level | $4.86 | $1.41 |
| Resistance Level | $6.15 | $2.01 |
| Average True Range (ATR) | 0.33 | 0.11 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 25.56 | 80.90 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.